Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Iran Pituitary Tumor Registry: Description of the Program and Initial Results Pubmed



Khamseh ME1 ; Mohajeri Tehrani MR2 ; Mousavi Z3 ; Malek M4 ; Imani M1 ; Tehrani NH1 ; Ghorbani M5 ; Akbari H1 ; Sarvghadi F6 ; Amouzegar A6 ; Esfahanian F7 ; Madani NH1 ; Emami Z1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran
  2. 2. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran
  3. 3. Endocrine Research Center, Imam Reza/Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  4. 4. Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran
  5. 5. Department of Neurosurgery and Neuro-Intervention, Firoozgar hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran
  6. 6. Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  7. 7. Department of Endocrinology, Imam Khomeini Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Archives of Iranian Medicine Published:2017


Abstract

Background: This study was designed to present initial results on clinical presentation, therapeutic modalities, and outcome information of patients with pituitary tumors registered in Iran Pituitary Tumor Registry (IPTR). Methods: We collected data from a web-based electronic medical records of patients with various pituitary tumors referred to four tertiary care centers in the country. Retrospective analysis was performed on demographic, clinical, and therapeutic information of 298 patients including 51 clinically nonfunctioning adenoma (CNFA), 85 acromegaly, 135 prolactinoma, and 27 Cushing’s disease (CD). Results: From October 2014 to July 2016, 298 people with the diagnosis of pituitary tumor were registered. Prolactinoma was the most prevalent tumor (45.3%), followed by Acromegaly (28.6%), CNFPA (17.1%), and CD (9%). Female dominance was seen among patients with prolactinoma and CD, while the majority of patients with CNFPA were male and acromegaly was equally distributed between men and women. Hypogonadal symptoms were almost always seen in all types of pituitary groups. Surgery alone was the most common therapeutic modality used in cases of acromegaly, CNFPA, and CD. However, medical therapy alone was frequently applied for cases of prolactinoma. Finally, biochemical cure was achieved in most cases of prolactinoma and CD, but only in 36.5% of acromegalics. Moreover, 80% of patients suffering from CNFPA showed no residual tumor in their imaging. Conclusion: In conclusion, this comprehensive tumor registry enables early identification, selection of best therapeutic approaches, and evaluation of long-term treatment outcomes. Furthermore, this registry can be used to improve surveillance protocols. © 2017 The Author(s).
Related Docs
1. Assessment of the Initial Results of Pituitary Tumor Registry at a Tertiary Hospital of Iran: 2009–2022, Journal of Diabetes and Metabolic Disorders (2024)
2. Non-Functioning Pituitary Macroadenoma: Surgical Outcomes, Tumor Regrowth, and Alterations in Pituitary Function—3-Year Experience From the Iranian Pituitary Tumor Registry, Hormones (2019)
3. Endoscopic Endonasal Approach to the Growth Hormone–Secreting Pituitary Adenomas: Endocrinologic Outcome in 68 Patients, World Neurosurgery (2018)
4. Pituitary Tumor Registry: A Multidisciplinary Program Protocol, Journal of Diabetes and Metabolic Disorders (2023)
Experts (# of related papers)
View all Related Experts
Mahnaz Pejman Sani (2)
Mohammad Reza Mohajeri Tehrani (2)